Quick Answer
Vir Biotechnology, Inc. reported Cash and Equivalents of $232.19 million for fiscal year 2025.
Vir Biotechnology, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $232.19M | +4.1% |
| 2024 | $222.95M | -7.7% |
| 2023 | $241.58M | -71.5% |
| 2022 | $848.63M | +144.0% |
| 2021 | $347.81M | -20.3% |
| 2020 | $436.57M | +299.3% |
| 2019 | $109.33M | +129.7% |
| 2018 | $47.60M | -74.7% |
| 2017 | $187.92M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $170.08M | +1.0% | -19.4% |
| June 30, 2025 | $211.10M | -28.9% | -22.8% |
| March 31, 2025 | $273.57M | +70.2% | +22.7% |
| December 31, 2024 | $222.95M | -7.7% | +32.4% |
| September 30, 2024 | $168.35M | -62.8% | -43.3% |
| June 30, 2024 | $296.86M | -55.5% | +84.7% |
| March 31, 2024 | $160.71M | -80.5% | -33.5% |
| December 31, 2023 | $241.58M | -71.5% | -46.6% |
- Vir Biotechnology, Inc. showed an increase of +4.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2017–2025 period, Vir Biotechnology, Inc.’s cash and equivalents has grown by 23.6% (from $187.92 million to $232.19 million).
- The most recent figure is from Vir Biotechnology, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: